Nasopharyngeal carcinoma: an ENT’s department 14-year experience
DOI:
https://doi.org/10.34631/sporl.3068Keywords:
Nasopharyngeal cancer, Head and neck cancer, Risk factors, EpidemiologyAbstract
Objectives: To analyse the population diagnosed with nasopharyngeal carcinoma over a 14-year period and evaluate the impact of clinical characteristics on overall survival.
Study Design: Retrospective.
Materials and Methods: Review of medical records and analysis of clinical variables, including sex, age, staging, histological subtype, presenting symptoms and their duration, presence of alcohol or tobacco use, EBV status, treatment administered, and overall survival.
Results: A total of 36 patients were included. The most common histological subtype was keratinizing squamous cell carcinoma (61.1%) with a median overall survival of 8,0 ± 6,1 months.
Conclusion: Age, sex, referral, presenting symptoms, symptom duration, staging, EBV status, treatment, and risk factors (smoking and alcohol use) did not have a statistically significant impact on overall survival. In our study, keratinizing carcinoma was associated with a significantly poorer prognosis (HR=7.3; p=0.026).
Downloads
References
Eduardo B, Raquel C, Rui M. Nasopharyngeal carcinoma in a south European population: epidemiological data and clinical aspects in Portugal. Eur Arch Otorhinolaryngol. 2010 Oct;267(10):1607-12. doi: 10.1007/s00405-010-1258-3.
Breda ELFR. Carcinoma da nasofaringe: Aspectos epidemiológicos clínicos e moleculares. [dissertation on the Internet]. Aveiro: [Universidade de Aveiro]; 2011. 188 p. Available from: http://hdl.handle.net/10773/3948
Lee N, Dimitrios Colevas A, Fu KK. Cancer of the nasopharynx. In: Leibel and Phillips Textbook of Radiation Oncology, 3rd ed. Philadelphia: Elsevier Saunders; 2010. 523-545 p. Available from: https://www.sciencedirect.com/science/article/pii/B9781416058977000287.
d'Espiney Amaro C, Montalvão P, Henriques P, Magalhães M, Olias J. Nasopharyngeal carcinoma: our experience. Eur Arch Otorhinolaryngol. 2009 Jun;266(6):833-8. doi: 10.1007/s00405-008-0822-6.
Badoual C. Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Oropharynx and Nasopharynx. Head Neck Pathol. 2022 Mar;16(1):19-30. doi: 10.1007/s12105-022-01449-2.
Bruce H. Haughey, Valerie J. Lund, Howard W. Francis, K. et al. Benign and Malignant Tumors of the Nasopharynx. In: Cummings Otolaryngology Head and Neck Surgery, 6th ed. Philadelphia: Elsevier Saunders; 2020.
Bray F, Haugen M, Moger TA, Tretli S, Aalen OO, Grotmol T. Age-incidence curves of nasopharyngeal carcinoma worldwide: bimodality in low-risk populations and aetiologic implications. Cancer Epidemiol Biomarkers Prev. 2008 Sep;17(9):2356-65. doi: 10.1158/1055-9965.EPI-08-0461.
Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1. doi: 10.3322/canjclin.49.1.33.
Chan AT, Grégoire V, Lefebvre JL, Licitra L, Hui EP, Leung SF. et al. Nasopharyngeal cancer: EHNS – ESMO – ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012 Oct:23 Suppl 7:vii83-5. doi: 10.1093/annonc/mds266.
Breda E, Catarino R, Azevedo I, Fernandes T, Barreira da Costa C, Medeiros R. Caracterización de la evolución clínica del carcinoma de la nasofaringe en una población portuguesa. Acta Otorrinolaringol Esp. [online] 2007 May;58(5):191-7. Available from: http://dx.doi.org/10.1016/S0001-6519(07)74911-7
Edge SB, Byrd DR, Compton CC, Fritz AG, Frederick L. Greene. et al (Eds.) AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2017
Chang ET, Ye W, Zeng YX, Adami HO. The evolving epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2021 Jun;30(6):1035-1047. doi: 10.1158/1055-9965.EPI-20-1702.
Guo R, Mao YP, Tang LL, Chen L, Sun Y, Ma J. The evolution of nasopharyngeal carcinoma staging. Br J Radiol. 2019 Oct;92(1102):20190244. doi: 10.1259/bjr.20190244.
Chua MLK, Wee JTS, Hui EP, Chan ATC. Nasopharyngeal carcinoma. Lancet. 2016 Mar 5;387(10022):1012-1024. doi: 10.1016/S0140-6736(15)00055-0.
Lertbutsayanukul C, Kannarunimit D, Prayongrat A, Chakkabat C, Kitpanit S, Hansasuta P. Prognostic value of plasma EBV DNA for nasopharyngeal cancer patients during treatment with intensity-modulated radiation therapy and concurrent chemotherapy. Radiol Oncol. 2018 Apr 28;52(2):195-203. doi: 10.2478/raon-2018-0016.
Ji X, Zhang W, Xie C, Wang B, Zhang G, Zhou F. Nasopharyngeal carcinoma risk by histologic type in central China: impact of smoking, alcohol and family history. Int J Cancer. 2011 Aug 1;129(3):724-32. doi: 10.1002/ijc.25696.
Guo SS, Huang PY, Chen QY, Liu H, Tang LQ, Zhang L. et al. The impact of smoking on the clinical outcome of locoregionally advanced nasopharyngeal carcinoma after chemoradiotherapy. Radiat Oncol. 2014 Nov 26:9:246. doi: 10.1186/s13014-014-0246-y.
Tang LL, Guo R, Zhang N, Deng B, Chen L, Cheng ZB et al. Effect of radiotherapy alone vs radiotherapy with concurrent chemoradiotherapy on survival without disease relapse in patients with low-risk nasopharyngeal carcinoma: a randomized clinical trial. JAMA. 2022 Aug 23;328(8):728-736. doi: 10.1001/jama.2022.13997.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Portuguese Journal of Otorhinolaryngology and Head and Neck Surgery
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
